- Delivering Pan India
Bdron® (Abiraterone Acetate) 250 mg and 500 mg tablets by BDR Pharmaceuticals. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Abiraterone Acetate 250 mg / 500 mg |
|---|---|
| Manufacturer | BDR Pharmaceuticals |
| Country | India |
| Pack size | 250 mg: 1 bottle of 120 tablets; 500 mg: 1 bottle of 60 tablets |
| Storage | Store in original pack as per carton instructions |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Bdron® (Abiraterone Acetate) 250 mg and 500 mg Tablets — CYP17 Inhibitor: A Sourcing Guide for Hospitals and Oncology Pharmacies
Bdron® is a brand of abiraterone acetate tablets, a CYP17 inhibitor, marketed by BDR Pharmaceuticals. According to the US prescribing information for the reference product (Zytiga®), abiraterone acetate is indicated, in combination with prednisone, for metastatic castration-resistant prostate cancer (CRPC) and metastatic high-risk castration-sensitive prostate cancer (CSPC). Indications for Bdron in India are defined by its approved pack insert and the Indian regulator. The decision to prescribe abiraterone, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Bdron® (abiraterone acetate) 250 mg and 500 mg tablets to hospitals, oncology centres and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.
Bdron contains abiraterone acetate, an oral inhibitor of CYP17, an enzyme involved in androgen production. Both Bdron presentations on this page contain the same active ingredient and differ in strength and pack count.
How it works, according to the label: The reference label describes abiraterone as a CYP17 inhibitor that blocks androgen biosynthesis in testicular, adrenal and prostatic tumour tissue, reducing circulating androgens such as testosterone.
The current US prescribing information for Zytiga® (abiraterone acetate; DailyMed) lists the following, in combination with prednisone. Indications in India may differ and are defined by the Indian regulator and the Bdron pack insert.
The studies below are summarised as published; they describe the evidence for abiraterone, the active ingredient, and are not a recommendation for any patient.
Bdron is a brand of abiraterone marketed in India; these trials were conducted with the reference product. The approved prescribing information governs.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Abiraterone Acetate 250 mg | Tablets (oral) | 1 bottle of 120 tablets |
| Abiraterone Acetate 500 mg | Tablets IP (oral) | 1 bottle of 60 tablets |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, oncology and urology department buyers, and pharmacies that source specialty oncology products. Abiraterone is prescribed and supervised by a physician, as described in the prescribing information.
The US prescribing information for Zytiga® reports that the most common adverse reactions (10% or more) were fatigue, arthralgia, hypertension, nausea, oedema, hypokalaemia, hot flush, diarrhoea, vomiting, upper respiratory infection, cough and headache. Warnings listed include mineralocorticoid excess, adrenocortical insufficiency and hepatotoxicity, which can be severe and fatal. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Bdron carton, bottle and leaflet. Keep in the original pack, out of reach of children.
Bdron is marketed by BDR Pharmaceuticals. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Bdron through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Bdron available in India?
A.K. Pharma supplies Bdron (abiraterone acetate) 250 mg and 500 mg tablets to hospitals and pharmacies in India. Contact us for current availability.
What does Bdron contain?
Abiraterone acetate, a CYP17 inhibitor, in 250 mg and 500 mg tablets.
Can I order a single bottle?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Bdron be stored?
As printed on the carton, bottle and leaflet, in the original pack.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
